• EMAIL
  • PRINT
  • PDF
  • Bookmark and Share

Education

  • J.D., The Catholic University of America Columbus School of Law, 2016
  • Ph.D., The University of Alabama at Birmingham, Neurobiology, 2012
  • B.A., The University of Mississippi, Biological Sciences, 2003

Bar Admissions

  • District of Columbia
  • Virginia

Memberships & Affiliations

Pauline Newman IP American Inn of Court

Daniel L. Flint, Ph.D.

  • |
Associate
  • T: 202.753.3357
    F: 202.354.5010

Daniel L. Flint is an associate in the Food & Drug Law Practice and the Intellectual Property/Information Technology Practice.

Dr. Flint advises diverse clients across regulated industry on a broad range of legal, regulatory, and policy matters impacting the development and commercialization of FDA-regulated products with a particular focus on clients working in the biopharmaceutical, in vitro diagnostic device (IVD), and food & dietary supplement industries.  He also assists clients in submitting petitions to FDA and USDA, commenting on agency guidance documents and proposed rules, and analyzing federal legislation.  Before entering private practice, Dr. Flint worked as a consultant for a biotechnology trade association where his portfolio of issues included industrial and agricultural biotechnology, renewable fuels, and patent post-grant proceedings.

During law school, Dr. Flint served as a legal extern with the U.S. House Judiciary Committee and with the U.S. Patent and Trademark Office where he worked on intellectual property (IP) issues such as patent litigation reform, patent subject matter eligibility (§ 101), and the protection and enforcement of U.S. IP rights.

Dr. Flint conducted his doctoral research in neurobiology pursuant to an NIH training grant (T32) where he investigated animal models of a rare neurological disorder and developed analytical methods to identify novel disease-related biomarkers and therapeutic targets.  Upon completion of his doctoral research, he worked as a technical advisor evaluating applications of emerging technologies such as integrated “omics” approaches, neurotechnology, and gene therapy & gene editing platforms.

Speaking

11/14/18
11/07/18
Introduction to Drug Law and Regulation - Food & Drug Law Institute
11/02/18
09/06/18
FDLI’s Training Course for FDA/CDER ORISE Fellows